. 2020 Feb 6;12(2):376. doi: 10.3390/cancers12020376

Table 6.

Comparative analysis of CD47 and PD-L1 expression among the primary tumor tissue and peripheral blood.

CD47 in Tumor cells	CD47 Expression patients (%)				CD47^high Expression patients (%)
CD47 in Tumor cells	Primary Tumor	CTCs	Positivity Concordance	Primary Tumor	CTCs	Positivity Concordance
All patients	88.5	84.6	76.9	19.2	53.8	11.5
Early	80	70	60	20	60	20
Metastatic	93.8	93.8	87.5	18.8	50	6.2
PD-L1 in Tumor cells	PD-L1 expression patients (%)				PD-L1^high expression patients (%)
PD-L1 in Tumor cells	Primary tumor	CTCs	Positivity concordance	Primary tumor	CTCs	Positivity concordance
All patients	34.6	30.8	7.7	11.5	23.1	3.8
Early	30	30	0	20	20	0
Metastatic	37.5	31.2	12.5	6.2	25	6.2
PD-L1 in Immune cells	PD-L1 expression patients (%)				PD-L1^high expression patients (%)
PD-L1 in Immune cells	TILs	PBMCs	Positivity concordance	TILs	PBMCs	Positivity concordance
All patients	64	20	16	44	8	4
Early	60	40	30	40	10	0
Metastatic	66.7	6.7	6.7	46.7	6.7	6.7

CD47 and PD-L1 expression on tumor cells and immune cells was in parallel investigated in matched primary tumor tissue and blood samples of patients with BC (total patients: n = 26; early setting: n = 10; metastatic setting: n = 16).